Lack of CD8 <sup>+</sup> T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer

DOI Web Site 2 Citations
  • Brendan L. Horton
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
  • Duncan M. Morgan
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
  • Noor Momin
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
  • Maria Zagorulya
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
  • Elen Torres-Mejia
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
  • Vidit Bhandarkar
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
  • K. Dane Wittrup
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
  • J. Christopher Love
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
  • Stefani Spranger
    Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.

Abstract

<jats:p> A lung cancer–specific form of CD8 <jats:sup>+</jats:sup> T cell dysfunction is established during T cell priming and contributes to ICB resistance. </jats:p>

Journal

  • Science Immunology

    Science Immunology 6 (64), eabi8800-, 2021-10-29

    American Association for the Advancement of Science (AAAS)

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top